PLoS ONE · 2009 · 67 citations · 49 references
MedicineCell BiologyOncologyTumor HeterogeneityTumor MicroenvironmentTumor ProgressionCancer ProgressionCancer Stem Cell BiologyCancer Stem Cell HeterogeneityCancer Stem CellsLung CancerStem Cell TumorigenicityCancer Stem Cell MarkersCancer Stem Cell ModelsCancer Stem Cell Phenotypic HeterogeneityCancer Stem-like CellsIntra-tumor HeterogeneityIntratumoral DiversityMalignant Pleural EffusionPleural Effusion Cytology
Malignant Pleural Effusions (MPE) may be useful as a model to study hierarchical progression of cancer and/or intratumoral heterogeneity. To strengthen the rationale for developing the MPE-model for these purposes, we set out to find evidence for the presence of cancer stem cells (CSC) in MPE and demonstrate an ability to sustain intratumoral heterogeneity in MPE-primary cultures. Our studies show that candidate lung CSC-expression signatures (PTEN, OCT4, hTERT, Bmi1, EZH2 and SUZ12) are evident in cell pellets isolated from MPE, and MPE-cytopathology also labels candidate-CSC (CD44, cMET, MDR-1, ALDH) subpopulations. Moreover, in primary cultures that use MPE as the source of both tumor cells and the tumor microenvironment (TME), candidate CSC are maintained over time. This allows us to live-sort candidate CSC-fractions from the MPE-tumor mix on the basis of surface markers (CD44, c-MET, uPAR, MDR-1) or differences in xenobiotic metabolism (ALDH). Thus, MPE-primary cultures provide an avenue to extract candidate CSC populations from individual (isogenic) MPE-tumors. This will allow us to test whether these cells can be discriminated in functional bioassays. Tumor heterogeneity in MPE-primary cultures is evidenced by variable immunolabeling, differences in colony-morphology, and differences in proliferation rates of cell subpopulations. Collectively, these data justify the ongoing development of the MPE-model for the investigation of intratumoral heterogeneity, tumor-TME interactions, and phenotypic validation of candidate lung CSC, in addition to providing direction for the pre-clinical development of rational therapeutics.
49
Prospective identification of tumorigenic breast cancer cells
Muhammad Al‐Hajj, Max S. Wicha, Adalberto Benito‐Hernández et al. · Proceedings of the National Academy of Sciences · 2003 · 10.4K citations · Full text
Medicine, Cell Biology, Oncology +11
The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
Sendurai A. Mani, Wenjun Guo, Mai-Jing Liao et al. · Cell · 2008 · 8.7K citations · Full text
Ahmedin Jemal, Rebecca L. Siegel, Elizabeth M. Ward et al. · CA A Cancer Journal for Clinicians · 2006 · 5.3K citations · Full text
A human colon cancer cell capable of initiating tumour growth in immunodeficient mice
Catherine O′Brien, Aaron Pollett, Steven Gallinger et al. · Nature · 2006 · 4.1K citations
Medicine, Cancer Biology, Oncology +11